High-Throughput Screening of Novel Organometallic Compounds for Potential Anticancer Activity

Introduction: Cancer still represents a substantial international challenge, and searching for new therapeutic agents is unceasing. Cancer development is assessed in this study through new organometallic compounds as potential cancer elimination agents using high-throughput screening (HTS) parameters. Methods: This study has examined a wide variety of organometallic compounds, including MCF-7 (breast cancer) line cells, A549 (lung cancer), and HCT-116 (colon cancer).Results: High-throughput screening identified three novel compounds, OM-101, OM-202, and OM-303, with potential anticancer activity against specific cancer cell lines. OM-101 exhibited high potency in MCF-7 breast cancer cells (IC50 = 1.2 μM) by inducing apoptosis, while OM-202 demonstrated the most potent activity in A549 lung cancer cells (IC50 = 0.8 μM) through DNA intercalation. OM-303, with an IC50 of 1.5 μM in HCT-116 colon cancer cells, was associated with reactive oxygen species (ROS) generation but requires further investigation. Validation assays confirmed these mechanisms, refining the IC50 values for OM-101 (1.1 μM), OM-202 (0.7 μM), and OM-303 (1.4 μM). These results highlight OM-101 and OM-202 as promising therapeutic candidates, with OM-303 necessitating additional studies to elucidate its potential.Conclusion: these findings collectively underscore the potential of OM-101 and OM-202 as strong therapeutic candidates, with OM-303 requiring further exploration to clarify its efficacy and mechanism